Distinct cortical and striatal actions of a β-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 50, 2016, Pages E8178-E8186

  Urs, Nikhil M ^a   Gee, Steven M ^b   Pack, Thomas F ^a   McCorvy, John D ^c   Evron, Tama ^a   Snyder, Joshua C ^a   Yang, Xiaobao ^d   Rodriguiz, Ramona M ^a   Borrelli, Emiliana ^e   Wetsel, William C ^a,e   Jin, Jian ^d   Roth, Bryan L ^c   O'Donnell, Patricio ^b   Caron, Marc G ^a   Snyder, Solomon H ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Arrestin; Biased signaling; Dopamine D2R; Fast spiking interneurons

Indexed keywords

ARIPIPRAZOLE; BETA ARRESTIN 2; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ETICLOPRIDE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; GUANINE NUCLEOTIDE BINDING PROTEIN; HALOPERIDOL; NEUROLEPTIC AGENT; UNC 9975A; UNC 9994A; UNCLASSIFIED DRUG; ADRBK1 PROTEIN, HUMAN; ADRBK1 PROTEIN, MOUSE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRD2 PROTEIN, MOUSE; LIGAND; PHENCYCLIDINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; CORTICAL EXCITABILITY; GENOTYPE; HEK293 CELL LINE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNEURON; LOCOMOTION; MEDIUM SPINY NEURON; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOPHARMACOTHERAPY; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; 129 MOUSE; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; BRAIN CORTEX; C57BL MOUSE; DRUG EFFECTS; FEMALE; KNOCKOUT MOUSE; MALE; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BETA-ARRESTIN 2; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE D2 RECEPTOR ANTAGONISTS; FEMALE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; INTERNEURONS; LIGANDS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENCYCLIDINE; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION;

EID: 85005965121     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1614347113     Document Type: Article

References (95)

1. Hopkins AL, Groom C.R. (2002) The druggable genome. Nat Rev Drug Discov 1(9): 727-730.
2. Allen JA, Roth B.L. (2011) Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 51:117-144.
3. Benovic JL, Strasser RH, Caron M.G., Lefkowitz R.J. (1986) Beta-adrenergic receptor kinase: Identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci USA 83(9):2797-2801.
4. Lohse MJ, Benovic JL, Codina J, Caron M.G., Lefkowitz R.J. (1990) beta-Arrestin: A protein that regulates beta-adrenergic receptor function. Science 248 (4962): 1547-1550.
5. Ferguson SS, et al (1996) Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271 (5247):363-366.
6. Goodman OB, Jr, et al. (1996) Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 383 (6599):447-450.
7. Laporte SA, et al (1999) The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA 96(7):3712-3717.
8. Attramadal H, et al (1992) Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 267(25):17882-17890.
9. Gainetdinov RR, Premont RT, Bohn L.M., Lefkowitz RJ, Caron M.G. (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27:107-144.
10. Luttrell LM, et al (1999) Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283 (5402):655-661.
11. Lefkowitz RJ, Shenoy S.K. (2005) Transduction of receptor signals by beta-arrestins. Science 308 (5721):512-517.
12. DeFea KA, et al (2000) The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA 97(20):11086-11091.
13. Urban JD, et al (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320(1):1-13.
14. Violin JD, Lefkowitz R.J. (2007) Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 28(8):416-422.
15. Walters RW, et al (2009) beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 119(5):1312-1321.
16. Packard MG, Knowlton B.J. (2002) Learning and memory functions of the Basal Ganglia. Annu Rev Neurosci 25:563-593.
17. Saint-Cyr J.A., Taylor AE, Nicholson K. (1995) Behavior and the basal ganglia. Adv Neurol 65:1-28.
18. Zhou QY, Palmiter R.D. (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83(7):1197-1209.
19. Schultz W (2002) Getting formal with dopamine and reward. Neuron 36(2):241-263.
20. Howes OD, Kapur S. (2009) The dopamine hypothesis of schizophrenia: Version III-the final common pathway. Schizophr Bull 35(3):549-562.
21. Bernheimer H, Birkmayer W, Hornykiewicz O., Jellinger K, Seitelberger F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415-455.
22. Pauls DL, Abramovitch A, Rauch S.L., Geller D.A. (2014) Obsessive-compulsive disorder: An integrative genetic and neurobiological perspective. Nat Rev Neurosci 15(6): 410-424.
23. Greengard P (2001) The neurobiology of slow synaptic transmission. Science 294 (5544):1024-1030.
24. Missale C, Nash SR, Robinson S.W., Jaber M., Caron M.G. (1998) Dopamine receptors: From structure to function. Physiol Rev 78(1):189-225.
25. Svenningsson P, et al (2003) Diverse psychotomimetics act through a common signaling pathway. Science 302 (5649):1412-1415.
26. Bateup HS, et al (2010) Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci USA 107(33):14845-14850.
27. Beaulieu JM, et al (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122(2):261-273.
28. Beaulieu JM, et al (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132(1):125-136.
29. Beaulieu JM, et al (2007) Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 27(4):881-885.
30. Urs NM, Snyder JC, Jacobsen J.P., Peterson SM, Caron M.G. (2012) Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci USA 109(50):20732-20737.
31. Creese I, Burt DR, Snyder S.H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192 (4238):481-483.
32. Seeman P, Lee T, Chau-Wong M, Wong K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261 (5562):717-719.
33. Allen JA, et al (2011) Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA 108(45):18488-18493.
34. 2 receptor agonists. J Med Chem 55(16):7141-7153.
35. Park SM, et al (2016) Effects of β-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in hypoglutamatergic mice. Neuropsychopharmacology 41(3):704-715.
36. Abi-Dargham A., Laruelle M. (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: Insights from brain imaging studies. Eur Psychiatry 20(1):15-27.
37. Keefe RS, Silva SG, Perkins D.O., Lieberman J.A. (1999) The effects of atypical antipsy-chotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 25(2):201-222.
38. King DJ (1998) Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 8(1):33-42.
39. Klewe IV, et al (2008) Recruitment of beta-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology 54(8):1215-1222.
40. Masri B, et al (2008) Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA 105(36):13656-13661.
41. Krasel C, Bünemann M, Lorenz K., Lohse M.J. (2005) Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation. J Biol Chem 280(10):9528-9535.
42. Ménard L., et al (1997) Synergistic regulation of beta2-adrenergic receptor sequestration: Intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization. Mol Pharmacol 51(5):800-808.
43. Zhang J, et al (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of muopioid receptor responsiveness. Proc Natl Acad Sci USA 95(12): 7157-7162.
44. Peterson SM, Pack TF, Caron M.G. (2015) Receptor, ligand and transducer contributions to dopamine D2 receptor functional selectivity. PLoS One 10(10):e0141637.
45. Erdtmann-Vourliotis M., Mayer P, Ammon S., Riechert U, Höllt V (2001) Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res 95(1-2):129-137.
46. Ahmed MR, Bychkov E, Gurevich V.V., Benovic JL, Gurevich E.V. (2008) Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. J Neurochem 104(6):1622-1636.
47. Del Arco A., Mora F, Mohammed A.H., Fuxe K. (2007) Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens. J Neural Transm (Vienna) 114(2): 185-193.
48. Suzuki Y, Jodo E, Takeuchi S., Niwa S, Kayama Y. (2002) Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats. Neuroscience 114(3):769-779.
49. Fell MJ, et al (2009) In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268). J Pharmacol Exp Ther 331(3):1126-1136.
50. White IM, et al (1995) Phencyclidine-induced increases in striatal neuron firing in behaving rats: Reversal by haloperidol and clozapine. J Neural Transm 102(2):99-112.
51. Anzalone A, et al (2012) Dual control of dopamine synthesis and release by pre-synaptic and postsynaptic dopamine D2 receptors. J Neurosci 32(26):9023-9034.
52. De Mei C., Ramos M, Iitaka C., Borrelli E. (2009) Getting specialized: Presynaptic and postsynaptic dopamine D2 receptors. Curr Opin Pharmacol 9(1):53-58.
53. Gerfen CR (1992) The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 15:285-320.
54. Kreitzer AC (2009) Physiology and pharmacology of striatal neurons. Annu Rev Neurosci 32:127-147.
55. Lidow MS, Goldman-Rakic PS, Rakic P., Innis R.B. (1989) Dopamine D2 receptors in the cerebral cortex: Distribution and pharmacological characterization with [3H]ra-clopride. Proc Natl Acad Sci USA 86(16):6412-6416.
56. Santana N, Mengod G, Artigas F. (2009) Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 19(4):849-860.
57. Vincent SL, Khan Y, Benes F.M. (1993) Cellular distribution of dopamine D1 and D2 receptors in rat medial prefrontal cortex. J Neurosci 13(6):2551-2564.
58. Lieberman JA, et al (2008) Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60(3): 358-403.
59. Powell SB, Geyer M.A. (2007) Overview of animal models of schizophrenia. Curr Protoc Neurosci 9:9.24.
60. Schmid CL, Streicher JM, Meltzer H.Y., Bohn L.M. (2014) Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a βarrestin2-independent activation of Akt. Neuropsychopharmacology 39(8):1902-1913.
61. Bohn LM, et al (2003) Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 23(32):10265-10273.
62. Tseng KY, et al (2008) A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. J Neurosci 28(48):12691-12699.
63. Tseng KY, O'Donnell P (2004) Dopamine-glutamate interactions controlling pre-frontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci 24(22):5131-5139.
64. Tseng KY, O'Donnell P (2007) Dopamine modulation of prefrontal cortical interneurons changes during adolescence. Cereb Cortex 17(5):1235-1240.
65. Akbarian S, et al (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52(4):258-266.
66. Thompson M, Weickert CS, Wyatt E, Webster M.J. (2009) Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatr Res 43(11):970-977.
67. Volk DW, Austin MC, Pierri J.N., Sampson AR, Lewis D.A. (2000) Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 57(3): 237-245.
68. Fung SJ, et al (2010) Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry 167(12): 1479-1488.
69. Hashimoto T, et al (2008) Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry 165(4): 479-489.
70. Nakazawa K, et al (2012) GABAergic interneuron origin of schizophrenia patho-physiology. Neuropharmacology 62(3):1574-1583.
71. Lewis DA, Curley AA, Glausier J.R., Volk D.W. (2012) Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 35(1):57-67.
72. Sohal VS, Zhang F, Yizhar O., Deisseroth K. (2009) Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459 (7247):698-702.
73. Cho KK, et al (2015) Gamma rhythms link prefrontal interneuron dysfunction with cognitive inflexibility in Dlx5/6(+/-) mice. Neuron 85(6):1332-1343.
74. Surmeier DJ, Ding J, Day M., Wang Z, Shen W. (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30(5):228-235.
75. Pycock CJ, Kerwin RW, Carter C.J. (1980) Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286 (5768):74-76.
76. Ventura R, et al (2004) Dopamine in the medial prefrontal cortex controls genotype-dependent effects of amphetamine on mesoaccumbens dopamine release and locomotion. Neuropsychopharmacology 29(1):72-80.
77. Weinberger DR (1987) Implications of normal brain development for the pathogen-esis of schizophrenia. Arch Gen Psychiatry 44(7):660-669.
78. Laruelle M, Abi-Dargham A (1999) Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies. J Psychopharmacol 13(4):358-371.
79. Slifstein M, et al (2015) Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72(4):316-324.
80. Kern RS, et al (2006) The neurocognitive effects of aripiprazole: An open-label comparison with olanzapine. Psychopharmacology (Berl) 187(3):312-320.
81. Rajagopal L, Massey BW, Huang M, Oyamada Y., Meltzer H.Y. (2014) The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des 20(31):5104-5114.
82. Kabanova A, et al (2015) Function and developmental origin of a mesocortical inhibitory circuit. Nat Neurosci 18(6):872-882.
83. Madisen L, et al (2015) Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. Neuron 85(5):942-958.
84. Madisen L, et al (2010) A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 13(1):133-140.
85. Bateup HS, et al (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11(8):932-939.
86. Du J, et al (2010) A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci USA 107(25):11573-11578.
87. Li YC, Xi D, Roman J., Huang YQ, Gao W.J. (2009) Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 29(49): 15551-15563.
88. Urs NM, Daigle TL, Caron M.G. (2011) A dopamine D1 receptor-dependent β-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 36(3):551-558.
89. Rossi J, et al (2011) Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab 13(2):195-204.
90. Heiman M, Kulicke R, Fenster R.J., Greengard P., Heintz N. (2014) Cell type-specific mRNA purification by translating ribosome affinity purification (TRAP). Nat Protoc 9(6):1282-1291.
91. Heiman M, et al (2014) Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci USA 111(12):4578-4583.
92. Livak KJ, Schmittgen T.D. (2001) Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402-408.
93. Lowe JD, et al (2015) Role of G protein-coupled receptor kinases 2 and 3 in μ-opioid receptor desensitization and internalization. Mol Pharmacol 88(2):347-356.
94. Zhu H, et al (2012) Quantitative analysis of focused a-to-I RNA editing sites by ultra-high-throughput sequencing in psychiatric disorders. PLoS One 7(8):e43227.
95. Cobb JA, et al (2013) Hippocampal volume and total cell numbers in major depressive disorder. J Psychiatr Res 47(3):299-306.